...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trillium

IMO,   on the Zenith side it is time to hire the best available investment banker firm  to maximize the proper valuation buyout  based on the Constellation latest sale of $1.8 Billion  I am pretty confident there has to other large BP players very interested in the Epigenetics field, especially now that Constellation Phar,ma has been sold.   I have to beleive one of the  current trial Collaborator partnerships with Zenith  has a strong interest in taking Zenith to a higher partnership  level or buyout.  Its time for Zenith to be sold which would give much needed credibility to RVX as a potential buyout or partnership target, , Anyone in Zenith management reading these forums....  Bueller bueller bueller ........

Share
New Message
Please login to post a reply